Use of Echocardiograms in the Medicare Population: A Diagnostic Tool in the Fight Against Severe Aortic Stenosis
Real-World Bleeding Risks in Non-Valvular Atrial Fibrillation Patients with Heart Failure: Contemporary HER Results Among Prescribed Apixaban, Dabigatran, Rivaroxaban, and Warfarin.
Real World Adherence to Blood Cholesterol Treatment Guidelines Among Physicians Treating Patients with Atherosclerotic Cardiovascular Disease – an EMR Analysis of an Integrated Delivery Network
Medical Resource Use and Cost Consequences of Hospitalization for Repositioning, Repair, or Removal of Implantable Cardioverter Defibrillator Transvenous Leads
Contemporary Results from EHR Study of Real-World Bleeding Risk Among Elderly and Overall Non-Valvular Atrial Fibrillation Patients Prescribed Apixaban, Dabigatran, Rivaroxaban and Warfarin
LDL-C Goal Achievement After Adding or Switching to Ezetimibe in Patients with Clinical Atherosclerotic Cardiovascular Disease or Probable HeFH
Incidence and Costs Related to Lead Damage Occurring Within the First Year After a Cardiac Implantable Electronic Device Replacement Procedure
Bleeding Risk for Non-Valvular AF Patients Prescribed Warfarin, or Standard Doses of Apixaban 5mg BID, Dabigatran 150mg BID or Rivaroxaban 20mg QD in Real-World Practice: Findings From EHR
